rs370331492
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP2PP3BS2
The NM_001035.3(RYR2):c.6320C>T(p.Thr2107Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000477 in 1,613,838 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. T2107T) has been classified as Likely benign.
Frequency
Consequence
NM_001035.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RYR2 | NM_001035.3 | c.6320C>T | p.Thr2107Met | missense_variant | 41/105 | ENST00000366574.7 | NP_001026.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RYR2 | ENST00000366574.7 | c.6320C>T | p.Thr2107Met | missense_variant | 41/105 | 1 | NM_001035.3 | ENSP00000355533.2 | ||
RYR2 | ENST00000609119.2 | n.6320C>T | non_coding_transcript_exon_variant | 41/104 | 5 | ENSP00000499659.2 | ||||
RYR2 | ENST00000660292.2 | c.6320C>T | p.Thr2107Met | missense_variant | 41/106 | ENSP00000499787.2 | ||||
RYR2 | ENST00000659194.3 | c.6320C>T | p.Thr2107Met | missense_variant | 41/105 | ENSP00000499653.3 |
Frequencies
GnomAD3 genomes AF: 0.0000855 AC: 13AN: 152020Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000883 AC: 22AN: 249170Hom.: 0 AF XY: 0.000104 AC XY: 14AN XY: 135172
GnomAD4 exome AF: 0.0000438 AC: 64AN: 1461700Hom.: 1 Cov.: 31 AF XY: 0.0000495 AC XY: 36AN XY: 727134
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.0000941 AC XY: 7AN XY: 74364
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 18, 2013 | The Thr2107Met variant in RYR2 has not been reported in individuals with cardiom yopathy, but has been identified in 1/8286 European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). Computationa l analyses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhen 2, and SIFT) suggest that this variant may impact the protein, though this infor mation is not predictive enough to determine pathogenicity. Additional informati on is needed to fully assess the variant's clinical significance. - |
Catecholaminergic polymorphic ventricular tachycardia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | May 30, 2024 | This variant is located in the RYR2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with catecholaminergic polymorphic ventricular tachycardia (Marschall et al., 2019). This variant has also been identified in 22/249170 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 08, 2023 | This variant is located in the RYR2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with catecholaminergic polymorphic ventricular tachycardia (Marschall et al., 2019). This variant has also been identified in 22/249170 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Catecholaminergic polymorphic ventricular tachycardia 1;C1832931:Arrhythmogenic right ventricular dysplasia 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Conduction disorder of the heart Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Sep 17, 2019 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 28, 2024 | Reported in association with arrythmogenic cardiomyopathy and catecholaminergic polymorphic ventricular tachycardia (CPVT) (PMID: 28404607, 31737537, 35819174); Not located in one of the three hot-spot regions of the RYR2 gene, where the majority of pathogenic missense variants occur (PMID: 19926015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35932045, 35819174, 28404607, 31737537, 19926015) - |
Catecholaminergic polymorphic ventricular tachycardia 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 28, 2023 | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 2107 of the RYR2 protein (p.Thr2107Met). This variant is present in population databases (rs370331492, gnomAD 0.02%). This missense change has been observed in individual(s) with arrhythmogenic cardiomyopathy with right dominant form and/or clinical features of catecholaminergic polymorphic ventricular tachycardia (PMID: 31737537, 35819174). ClinVar contains an entry for this variant (Variation ID: 178121). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RYR2 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Arrhythmogenic right ventricular dysplasia 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 06, 2018 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 05, 2024 | The p.T2107M variant (also known as c.6320C>T), located in coding exon 41 of the RYR2 gene, results from a C to T substitution at nucleotide position 6320. The threonine at codon 2107 is replaced by methionine, an amino acid with similar properties. This alteration has been detected in a cohort referred for whole exome sequencing and in a cohort referred for suspicion of various arrhythmogenic disorders (Landstrom AP et al. Circ Arrhythm Electrophysiol, 2017 Apr;10; Marschall C et al. Cardiovasc Diagn Ther, 2019 Oct;9:S292-S298; Bajaj A et al. Hum Genomics, 2022 Aug;16:30). This variant has also been reported in cardiomyopathy cohorts (Ware SM et al. Am J Hum Genet, 2022 Feb;109:282-298; Goudal A et al. Hum Mutat, 2022 Sep;43:1333-1342). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at